Adjuvant Chemotherapy for Resected Non-Small Cell Lung Cancer

Seminars in Thoracic and Cardiovascular Surgery

Volumn 20, Issue 3, 2008, Pages 198-203

  Wakelee, Heather ^a   Chhatwani, Laveena ^b  

^a STANFORD CANCER INSTITUTE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

adjuvant; chemotherapy; early stage lung cancer

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALKYLATING AGENT; BEVACIZUMAB; CANCER VACCINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MELANOMA ANTIGEN 3; MITOMYCIN; NAVELBINE; PACLITAXEL; PLACEBO; TEGAFUR; URACIL; VINBLASTINE; VINDESINE;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PNEUMONECTOMY; TREATMENT OUTCOME;

EID: 56349169930     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2008.09.001     Document Type: Article

References (27)

1. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
2. Goldstraw P., Crowley J., Chansky K., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumors. J Thorac Oncol 2 (2007) 706-714
3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311 (1995) 899-909
4. Burdett S., Stewart L.A., and Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 1 (2006) 611-621
5. Nicolson M., Gilligan D., Smith I.E., et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): first results in the MRC LU22/NVALT/EORTC 08012 multicenter randomized trial. J Clin Oncol 25 (2007) 389s (abstract 7518)
6. Scagliotti G.V., Pastorino U., Vansteenkiste J.F., et al. A phase III randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early-stage non-small cell lung cancer (NSCLC): follow-up data of Ch.E.S.T. J Clin Oncol 26 (2008) 399s (abstract 508)
7. Keller S.M., Adak S., Wagner H., et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 343 (2000) 1217-1222
8. Waller D., Peake M.D., Stephens R.J., et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the big lung trial. Eur J Cardiothorac Surg 26 (2004) 173-182
9. Scagliotti G.V., Fossati R., Torri V., et al. Randomized study of adjuvant chemotherapy for completely resected stage I. II, or IIIA non-small cell lung cancer. J Natl Cancer Inst 95 (2003) 1453-1461
10. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350 (2004) 351-360
11. Le Chevalier T., Arriagada R., Bergman B., et al. Long-term results of the international adjuvant lung cancer trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC). J Clin Oncol 26 (2008) 398s (abstract 7507)
12. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
13. Pepe C., Hasan B., Winton T.L., et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR. 10. J Clin Oncol 25 (2007) 1553-156
14. Strauss G.M., Herndon J., Maddaus M.A., et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of cancer and leukemia group B (CALGB) protocol 9633. J Clin Oncol 22 (2004) 621s (abstract 7019)
15. Douillard J.Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol 7 (2006) 719-727
16. Pignon J.P., Tribodet H., Scagliotti G.V., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26 (2008) 3552-3559
17. Strauss G.M., Herndon J.E., Maddaus M.A., et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update on cancer and leukemia group B (CALGB) protocol 9633. J Clin Oncol 24 (2006) 365s (abstract 7007)
18. Hamada C., Ohta M., Wada H., et al. Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small cell lung cancer. J Clin Oncol 22 (2004) 617s (abstract 7002)
19. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006) 983-991
20. Zheng Z., Chen T., Li X., et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356 (2007) 800-808
21. Potti A., Mukherjee S., Petersen R., et al. A genomic strategy to refine prognosis in early-stage non-small cell lung cancer. N Engl J Med 355 (2006) 570-580 2006
22. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355 (2006) 2542-2550
23. Manegold C., von Pawel J., Zatloukal P., et al. Randomized, double-blind multicenter phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): B017704. J Clin Oncol 25 (2007) 967s (abstract LBA7514)
24. Kelly K., Chansky K., Gaspar L.E., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer: SWOG S0023. J Clin Oncol 26 (2008) 2450-2456
25. Ardizzoni A., Boni L., Tiseo M., et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99 (2007) 847-857
26. Ettinger D.S., Bepler G., Bueno R., et al. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 4 (2006) 548-582
27. Pisters K.M., Evans W.K., Azzoli C.G., et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non-Small Cell Lung Cancer Guideline. J Clin Oncol 25 (2007) 5506-5518